Merck & Co. Executive Summary Case Study Goal The goal of this case study is to examine the current operations of Merck & Co. Inc. and determine areas of potential concern‚ evaluate the effectiveness of the current business model‚ and propose a plan of action to grow Merck & Co. Inc. to be the largest pharmaceutical company in the world. Methods of Analysis This case study will strive to identify areas of concern and opportunity‚ offer solutions‚ and make projections based upon historic data
Premium Financial ratio Financial ratios Strategic management
A Discussion on the Company’s Decision Making Process‚ Group Behavior and Organizational Structure Abstract Merck is a pharmaceutical and medical researching company that is dealing with managerial challenges in their daily business operations. Their background and their issues regarding the matter will then help one understand how the actual picture of the real accounts of the managerial decision processes that happen to actual multinational company operations. Having been
Premium Corporation Business Company
MERCK: OPEN FOR INNOVATION? Founded in 1891 as an American subsidiary of his German namesake‚ Merck was once considered the “undisputed king of the pharmaceutical industry with ground‐ breaking drugs”(The Chief Executive 2003). But for the last decade‚ Merck has gone through a period of stagnation; it began to lose exclusivity patents on blockbuster drugs and has witnessed Pfizer’s rise to top place in the industry. It seemed now that internal R&D that was once the company’s main asset would
Premium Pharmaceutical industry
Merck‚ the FDA‚ and the VIOXX Recall MBA 520-D4C2 Ethics & Leadership in a Global Environment April 22‚ 2012 Merck and Vioxx Recall Did Merck act in social and ethical manner? In 2005‚ Merck was ranked fourth in sales among pharmaceutical companies. Merck had released the drug Vioxx‚ for treating Osteoarthritis in late 1990. Merck as a company has a reputation of being one of the most ethical and
Premium Marketing Brand Management
In the year 2000‚ Merck produced a controversial product called Vioxx. Four years later it gained worldwide attention because of the drug’s potential cardiovascular risks. This was detrimental to the company’s reputation because it was alleged Merck knowingly distributed Vioxx despite its risk. Both Barbara Martinez and Anne W. Mathews of the Wall Street Journal wrote articles into the investigation of Vioxx. Their article suggests Merck knew the dangers of Vioxx at an early stage of its clinical
Premium Clinical trial
Introduction and Situational Analysis Merck and River Blindness ethical dilemma is whether to pursue research that may or may affect the profits‚ or to choose a safer choice and go for profit rather than researching the drug. The outcome from researching the drug could possibly lead to healing the deadly and dangerous disease known as River Blindness. This drug is known to kill the parasite that has caused the disease. The problem with this situation was that the consumers of the drug could not pay
Premium Pharmacology Medicine Ethics
Merck is a global research-driven pharmaceutical company dedicated to putting patients first. Merck’s highest priority areas are Alzheimer’s disease‚ atherosclerosis‚ cardiovascular disease‚ diabetes‚ novel vaccines‚ obesity‚ oncology‚ pain and sleep disorders. In addition‚ and importantly for licensing‚ the following other areas remain of high interest for focused investment in new compounds and mechanisms: antibiotics‚ antifungals‚ antivirals (HCV and HIV)‚ asthma‚ COPD‚ neurodegeneration‚ ophthalmology
Premium RNA Protein Immune system
Strategy Case Analysis Merck & Co.: Evaluating a Drug Licensing Opportunity Introduction: Davanrik is a new drug developed by LAB Pharmaceuticals‚ which has the potential to treat depression and obesity. Davanrik was initially developed to treat depression by stimulating the receptor in the serotonin system that promotes anti-depression. However‚ it was discovered that Davanrik also blocks the receptor that causes hunger. LAB Pharmaceuticals obtained a patent for Davanrik with a max remaining
Premium
3rd‚ 2014 Case 5: Merck‚ the FDA‚ and the Vioxx Recall Section I Merck was one of the world’s leading pharmaceutical firms. The company ranked 4th I sales after Pfizer and Johnson & Johnson and it ranked 5th in assets and market value. Merck ranked 1st in profits‚ earning $7.33 billion on $30.78 billion in sales. In 2006‚ Merck faced major challenges with their once best selling prescription painkillers‚ Vioxx which was pulled off the market in September of 2004 after Merck learned it increased
Free Pharmacology Food and Drug Administration
patent. In 1995‚ Merck entered into a licensed agreement and collaboration to hold the rights to market Gardisil in all countries accept Australia and New Zealand. Merck was invested heavily in Gardasil‚ spending $1.2 billion in fifteen years before seeking approval from the FDA. After results of all phase trials were impressive‚ Merck moved for FDA approval. Merck hoped to receive approval before a competitive drug‚ known as Cervarix was approved. If so‚ it would guarantee Mercks first mover advantage
Premium Human papillomavirus HPV vaccine Cervical cancer